Alkermes plc. (ALKS)
Compare with another name Open in your desk ↗
Alkermes plc. (ALKS) reported revenue of $496 million for Q2 FY2026, the quarter ended 30 June 2026, up 27.0% on the same quarter a year earlier. Net income was $501,000, down 99.4% on the year, and diluted earnings per share $0.00. The figures are the company's own, from the 10-Q it filed with the SEC on 28 July 2026.
Revenue$496 millionup 27.0%
Net income$501,000down 99.4%
Diluted EPS$0.00
QuarterQ2 FY2026ended 30 June 2026
Alkermes plc. (ALKS) in brief
Alkermes plc. (ALKS) reported revenue of $1.5 billion for fiscal 2025, the year ended 31 December 2025, down 5.2% on the year before.
Read more
Net income was $242 million and diluted earnings per share $1.43. Revenue was $1.6 billion in fiscal 2024, $1.7 billion in fiscal 2023, $1.1 billion in fiscal 2022 and $1.2 billion in fiscal 2021. Net income in the same years was $367 million, $356 million, a loss of $158 million and a loss of $48 million. Over the twelve months to 30 June 2026, Alkermes plc. reported revenue of $1.7 billion and net income of $66 million. Revenue grew 7.3% a year, compounded, over the five years to fiscal 2025. Alkermes plc. had 168 million shares outstanding at the latest filed count. At 30 June 2026 it carried $1.5 billion of debt and $512 million of cash. At the close of 9 October 2026 the market cap of Alkermes plc. was $6.8 billion, 106.9 times its earnings over the last twelve months.Ratios
From the filings
ROE3.7%
ROCE3.5%
Operating margin7.0%
Net margin4.0%
FCF marginn/a
Interest cover1.98
Debt to equity0.84
Cash conversion3.80
Share count, 1 year1.5%
Sales CAGR, 3 years9.9%
Profit CAGR, 3 yearsn/a
EPS, TTM$0.38
At the close of 9 October 2026
Price$40.63
Market cap$6.8 billion
Stock P/E106.92
Price to book3.76
EV / EBITDA43.72
Dividend yieldn/a
Market cap / sales4.08
52-week high$55.22
52-week low$27.20
Price, 1 year29.5%
Price CAGR, 3 years12.7%
Price CAGR, 5 years5.1%
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Alkermes plc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.ALKSgreeksoup.ai
Daily prices to 9 October 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.The public record on ALKS
| Filings | 30 in twelve months: 20 current reports (8-K), about 11 regulation FD disclosure; 6 results of operations; 5 other events; 4 officer or director change; 4 material agreement |
| Planned insider sales | 28 Form 144 notices in twelve months, $9.7 million; latest 2 October 2026 |
| Options tape | put/call 0.76 by open interest at the 9 October 2026 close; the straddle prices a 6.1% move to 16 October 2026 |
| 13F holders | 7 of the followed funds hold it; largest Renaissance Technologies; 6 Schedule 13D or 13G filings in twelve months |
| Insider trading | 34 sales and 0 purchases on Form 4 in twelve months |
| Congress | 1 House trade disclosed in six months |
| Short interest | 17.8 million shares short, 6.28 days to cover at 30 September 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 6 earnings press releases, each linked |
Quarterly results, the last 12 quarters
| Q3 FY2023 † | Q4 FY2023 * † | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 381 | 377 | 350 | 399 | 378 | 430 | 307 | 391 | 394 | 385 | 393 | 496 |
| Cost of revenue | 61.5 | 70.1 | 58.6 | 61.5 | 63.1 | 62.1 | 49.2 | 49.5 | 51.6 | 46.2 | 61.6 | 98.1 |
| Gross profit | 319 | 307 | 292 | 338 | 315 | 368 | 257 | 341 | 343 | 338 | 331 | 398 |
| Gross margin | 84% | 81% | 83% | 85% | 83% | 86% | 84% | 87% | 87% | 88% | 84% | 80% |
| R&D | 64.9 | 73.9 | 67.6 | 59.6 | 59.9 | 58.2 | 71.8 | 77.4 | 81.7 | 93.0 | 103 | 113 |
| SG&A | 156 | 170 | 180 | 168 | 150 | 147 | 172 | 171 | 172 | 187 | 265 | 218 |
| Operating income | 89.2 | 54.6 | 43.3 | 110 | 105 | 163 | 13.8 | 93.0 | 89.1 | 58.1 | -48.3 | 18.4 |
| Operating margin | 23% | 14% | 12% | 28% | 28% | 38% | 4% | 24% | 23% | 15% | -12% | 4% |
| Interest expense | 6.0 | 6.1 | 6.0 | 6.0 | 6.0 | 4.6 | 0.0 | 0.0 | 0.0 | 12.3 | 20.9 | 25.9 |
| Pre-tax income | 92.7 | 58.3 | 46.9 | 117 | 110 | 170 | 25.5 | 105 | 101 | 60.4 | -61.9 | -1.9 |
| Tax rate | 1% | -175% | 17% | 19% | 16% | 14% | 12% | 17% | 18% | 18% | n/a | n/a |
| Net income | 47.8 | 113 | 36.8 | 91.4 | 92.4 | 147 | 22.5 | 87.1 | 82.8 | 49.3 | -66.5 | 0.5 |
| Net margin | 13% | 30% | 11% | 23% | 24% | 34% | 7% | 22% | 21% | 13% | -17% | 0% |
| Diluted EPS | $0.28 | $0.69 | $0.21 | $0.53 | $0.55 | $0.88 | $0.13 | $0.52 | $0.49 | $0.29 | -$0.40 | $0.00 |
| Operating cash flow | 99.7 | 107 | 21.1 | 146 | 81.6 | 190 | 98.8 | 150 | 102 | 170 | -166 | 145 |
| Capital expenditure | 14.5 | 17.0 | 8.3 | 7.1 | 8.3 | 9.8 | 10.1 | 13.0 | 17.3 | n/a | 4.1 | 8.1 |
| Free cash flow | 85.3 | 90.2 | 12.8 | 139 | 73.3 | 181 | 88.7 | 137 | 84.4 | n/a | -170 | 137 |
| Buybacks | n/a | n/a | n/a | n/a | 116 | n/a | n/a | n/a | n/a | n/a | 27.7 | 0.0 |
| Shares outstanding | 167m | 167m | 169m | 166m | 162m | 162m | 165m | 165m | 165m | 166m | 166m | 168m |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Income statement (profit and loss), 12 fiscal years and the trailing twelve months
Play it forward: change any box and its column follows; every box opens at the company's own record, shown under the row's name, and says when you set it outside every year in the table.
Read more
Each column runs from the last twelve months as filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 65 peers in Pharmaceutical Products (11.1% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 47 peers in Pharmaceutical Products (23.3). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| FY2014 † | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 † | FY2022 † | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 619 | 628 | 746 | 903 | 1,094 | 1,171 | 1,039 | 1,174 | 1,112 | 1,663 | 1,558 | 1,476 | 1,668 |
| Cost of revenue | 176 | 139 | 132 | 155 | 176 | 180 | 178 | 197 | 218 | 253 | 245 | 196 | 257 |
| Gross profit | 443 | 489 | 614 | 749 | 918 | 991 | 860 | 976 | 894 | 1,410 | 1,312 | 1,279 | 1,410 |
| Gross margin | 71.6% | 77.9% | 82.3% | 82.9% | 83.9% | 84.6% | 82.8% | 83.2% | 80.4% | 84.8% | 84.2% | 86.7% | 84.6% |
| Research and development | 272 | 344 | 387 | 413 | 425 | 513 | 395 | 291 | 273 | 271 | 245 | 324 | 391 |
| Selling, general and administrative | 200 | 312 | 374 | 422 | 526 | 599 | 539 | 550 | 591 | 690 | 645 | 702 | 841 |
| Operating income | -87.1 | -224 | -209 | -148 | -99.1 | -175 | -112 | 97.7 | -6.1 | 414 | 421 | 254 | 117 |
| Operating margin | -14.1% | -35.7% | -28.0% | -16.4% | -9.1% | -15.0% | -10.8% | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% | 7.0% |
| Interest expense | 13.4 | 13.2 | 14.9 | 12.0 | 15.4 | 13.6 | 8.7 | 11.2 | 13.0 | 23.0 | 22.6 | 12.3 | 59.1 |
| Pre-tax income | -14.0 | -224 | -214 | -143 | -127 | -197 | -96.5 | 87.7 | -31.1 | 422 | 444 | 291 | 97.3 |
| Income tax | 16.0 | 3.2 | -5.9 | 14.7 | 12.3 | -0.4 | 14.3 | 11.3 | 2.0 | -97.6 | 71.6 | 49.8 | 31.2 |
| Effective tax rate | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12.9% | n/a | -23.2% | 16.1% | 17.1% | 32.1% |
| Net income | -30.1 | -227 | -208 | -158 | -139 | -197 | -111 | -48.2 | -158 | 356 | 367 | 242 | 66.1 |
| Net margin | -4.9% | -36.2% | -28.0% | -17.5% | -12.7% | -16.8% | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% | 4.0% |
| Diluted EPS | -$0.21 | -$1.52 | -$1.38 | -$1.03 | -$0.90 | -$1.25 | -$0.70 | -$0.30 | -$0.97 | $2.10 | $2.17 | $1.43 | $0.38 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
From each year's 10-K, linked; TTM is the last four quarters.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.Revenue by region
| FY2023 | FY2024 | FY2025 | Share latest year | |
|---|---|---|---|---|
| United States | 1,492 | 1,410 | 1,373 | 93.0% |
| Rest of world | 170 | 146 | 102 | 6.9% |
| Ireland | 1.2 | 1.3 | 0.8 | 0.1% |
United StatesRest of worldIreland
$ million; hover a block for its figure and share
From the latest 10-K, in the company's own words.
Read more
A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Cash flow and capital returned
Follow the cash: free cash flow, which is operating cash flow less capital expenditure and share-based pay, for five years and after, in today's money.
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the last twelve months as filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 65 peers in Pharmaceutical Products (11.1% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| FY2014 † | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 † | FY2022 † | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 11.1 | -40.4 | -63.8 | 19.2 | 99.3 | 72.1 | 82.8 | 102 | 21.0 | 401 | 439 | 521 | 251 |
| Capital expenditure | 33.7 | 52.9 | 43.7 | 51.3 | 69.4 | 90.9 | 42.2 | 28.0 | 38.3 | 48.0 | 33.5 | 40.4 | n/a |
| Free cash flow | -22.5 | -93.2 | -107 | -32.1 | 29.9 | -18.9 | 40.6 | 73.7 | -17.2 | 353 | 406 | 480 | n/a |
| Free cash flow margin | -3.6% | -14.8% | -14.4% | -3.6% | 2.7% | -1.6% | 3.9% | 6.3% | -1.5% | 21.2% | 26.0% | 32.5% | n/a |
| Cash from investing | n/a | -43.5 | 127 | -18.4 | -22.2 | -142 | -11.5 | -66.2 | -64.5 | 53.4 | -111 | 295 | -1,764 |
| Cash from financing | n/a | 40.9 | -58.2 | 4.1 | -1.6 | 6.8 | -2.2 | 29.1 | -1.6 | -290 | -494 | 12.4 | 1,503 |
| Depreciation and amortisation | 98.1 | 85.6 | 94.3 | 98.5 | 104 | 80.4 | 81.9 | 78.7 | 77.9 | 74.9 | 28.5 | 27.2 | 61.6 |
| Share-based compensation | 59.6 | 97.3 | 94.4 | 83.9 | 105 | 101 | 90.2 | 87.6 | 94.3 | 101 | 96.6 | 98.7 | 118 |
| Buybacks | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 200 | n/a | n/a |
| Diluted shares, weighted | 145m | 149m | n/a | n/a | n/a | n/a | 159m | 161m | 164m | 170m | 169m | 169m | 173m |
| Shares outstanding at period end | 148m | 151m | 152m | 154m | 156m | 158m | 159m | 162m | 164m | 167m | 162m | 166m | 168m |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Cash paid in the year, from the cash flow statement.
Read more
The dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.Balance sheet at year end
| FY2014 † | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 † | FY2022 † | FY2023 | FY2024 | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | |||||||||||||
| Shareholders' equity | 1,397 | 1,314 | 1,209 | 1,203 | 1,171 | 1,085 | 1,067 | 1,113 | 1,044 | 1,203 | 1,465 | 1,819 | 1,809 |
| Debt | 356 | 350 | 284 | 278 | 276 | 274 | 272 | 293 | 290 | 288 | 0.0 | 0.0 | 1,525 |
| Operating lease liabilities | n/a | n/a | n/a | n/a | n/a | 5.3 | 119 | 104 | 76.3 | 75.7 | 69.4 | 63.3 | 62.0 |
| Other liabilities | 169 | 192 | 233 | 316 | 377 | 440 | 491 | 515 | 554 | 570 | 521 | 604 | 998 |
| Total liabilities and equity | 1,921 | 1,856 | 1,726 | 1,797 | 1,825 | 1,805 | 1,950 | 2,024 | 1,964 | 2,136 | 2,056 | 2,487 | 4,393 |
| Owned | |||||||||||||
| Fixed assets | 266 | 255 | 265 | 285 | 310 | 362 | 350 | 341 | 223 | 227 | 228 | 222 | 218 |
| Goodwill | 94.2 | 92.9 | 92.9 | 92.9 | 92.9 | 92.9 | 92.9 | 92.9 | 83.0 | 83.0 | 83.0 | 83.0 | 594 |
| Intangible assets | 479 | 379 | 318 | 256 | 191 | 151 | 111 | 74.0 | 37.7 | 2.0 | 0.9 | 0.8 | 1,761 |
| Investments | 578 | 618 | 433 | 399 | 353 | 411 | 387 | 428 | 448 | 356 | 534 | 200 | 180 |
| Cash and equivalents | 224 | 181 | 186 | 191 | 267 | 204 | 273 | 338 | 292 | 457 | 291 | 389 | 512 |
| Receivables | 152 | 155 | 191 | 234 | 292 | 257 | 275 | 313 | 288 | 332 | 385 | 334 | 456 |
| Inventory | 51.4 | 38.4 | 63.0 | 93.3 | 90.2 | 102 | 126 | 150 | 181 | 186 | 183 | 197 | 299 |
| Other assets | 77.4 | 136 | 177 | 246 | 229 | 226 | 335 | 287 | 411 | 492 | 352 | 1,062 | 372 |
| Total assets | 1,921 | 1,856 | 1,726 | 1,797 | 1,825 | 1,805 | 1,950 | 2,024 | 1,964 | 2,136 | 2,056 | 2,487 | 4,393 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
At the fiscal year end; the TTM column is the latest quarter end.
Read more
Both totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.Compounded growth
| 10 years | 5 years | 3 years | TTM | |
|---|---|---|---|---|
| Sales growth, compounded | 8.9% | 7.3% | 9.9% | 10.8% |
| Profit growth, compounded | n/a | n/a | n/a | -81.0% |
| Return on equity, average | -2.2% | 9.7% | 22.6% | 13.3% |
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read more
Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.Questions
What was Alkermes plc.'s revenue in fiscal 2025?
Alkermes plc. (ALKS) reported revenue of $1.5 billion for fiscal 2025, the year ended 31 December 2025, down 5.2% on the year before.
How much did Alkermes plc. earn in fiscal 2025?
Net income was $242 million for fiscal 2025, and diluted earnings per share $1.43.
What is Alkermes plc.'s P/E ratio?
At the close of 9 October 2026, Alkermes plc. traded at 106.9 times its earnings over the twelve months to 30 June 2026.
What is Alkermes plc.'s market cap?
The market cap of Alkermes plc. was $6.8 billion at the close of 9 October 2026.
How much debt does Alkermes plc. have?
At 30 June 2026 Alkermes plc. carried $1.5 billion of debt and $512 million of cash.
Peers: Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.11 trillion | 39.55 | 78.8% | n/a | 49.6% | 1.41 | 0.5% |
| Johnson & Johnson JNJ | $630.1 billion | 30.30 | 24.8% | n/a | 8.1% | 0.44 | 2.0% |
| AbbVie Inc. ABBV | $488.4 billion | 78.08 | n/a | 26.2% | 10.4% | n/a | 2.5% |
| Merck & Co., Inc. MRK | $359.1 billion | 116.46 | 7.6% | n/a | 4.6% | 1.29 | 2.3% |
| Novartis AG NVS * | $274.2 billion | 20.10 | 30.3% | n/a | 8.4% | 0.62 | 2.9% |
| AstraZeneca PLC AZN * | $246.9 billion | 24.34 | 21.0% | 23.4% | 8.6% | 0.57 | 2.0% |
| Abbott Laboratories ABT | $173.5 billion | 32.23 | 10.6% | 15.8% | 8.1% | 0.58 | 2.4% |
| Novo Nordisk A/S NVO * | $172.4 billion | 11.16 | 52.8% | 41.3% | 6.4% | 0.67 | 4.5% |
| Pfizer Inc. PFE | $161.1 billion | 37.20 | 5.1% | n/a | -0.2% | 0.71 | 6.1% |
| Vertex Pharmaceuticals Inc. VRTX | $129.3 billion | 29.70 | 21.8% | 38.0% | 10.2% | 0.00 | n/a |
| Bristol-Myers Squibb Co. BMY | $120.7 billion | 13.02 | 41.6% | 24.2% | 3.1% | 1.92 | 4.2% |
| Sanofi SNY * | $97.7 billion | 11.17 | 10.9% | n/a | 6.2% | 0.26 | 5.5% |
All 70 in Pharmaceutical Products
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Eli Lilly & Co. LLY | $1.11 trillion | 39.55 | 78.8% | n/a | 49.6% | 1.41 | 0.5% |
| Johnson & Johnson JNJ | $630.1 billion | 30.30 | 24.8% | n/a | 8.1% | 0.44 | 2.0% |
| AbbVie Inc. ABBV | $488.4 billion | 78.08 | n/a | 26.2% | 10.4% | n/a | 2.5% |
| Merck & Co., Inc. MRK | $359.1 billion | 116.46 | 7.6% | n/a | 4.6% | 1.29 | 2.3% |
| Novartis AG NVS * | $274.2 billion | 20.10 | 30.3% | n/a | 8.4% | 0.62 | 2.9% |
| AstraZeneca PLC AZN * | $246.9 billion | 24.34 | 21.0% | 23.4% | 8.6% | 0.57 | 2.0% |
| Amgen Inc. AMGN | $224.3 billion | 25.79 | 74.8% | 30.0% | 9.1% | 4.90 | 1.8% |
| Gilead Sciences, Inc. GILD | $187.6 billion | n/a | -27.4% | -8.2% | 5.5% | 2.22 | 2.1% |
| Abbott Laboratories ABT | $173.5 billion | 32.23 | 10.6% | 15.8% | 8.1% | 0.58 | 2.4% |
| Novo Nordisk A/S NVO * | $172.4 billion | 11.16 | 52.8% | 41.3% | 6.4% | 0.67 | 4.5% |
| Pfizer Inc. PFE | $161.1 billion | 37.20 | 5.1% | n/a | -0.2% | 0.71 | 6.1% |
| Vertex Pharmaceuticals Inc. VRTX | $129.3 billion | 29.70 | 21.8% | 38.0% | 10.2% | 0.00 | n/a |
| Bristol-Myers Squibb Co. BMY | $120.7 billion | 13.02 | 41.6% | 24.2% | 3.1% | 1.92 | 4.2% |
| Sanofi SNY * | $97.7 billion | 11.17 | 10.9% | n/a | 6.2% | 0.26 | 5.5% |
| GSK plc GSK * | $93.3 billion | 12.66 | 34.9% | 24.3% | 4.1% | 1.08 | 3.6% |
| Moderna, Inc. MRNA | $89.8 billion | n/a | -46.6% | -149.0% | -27.6% | 0.09 | n/a |
| Regeneron Pharmaceuticals, Inc. REGN | $79.1 billion | 18.45 | 13.7% | 24.7% | 9.3% | 0.06 | 0.5% |
| Takeda Pharmaceutical Company Limited TAK * | $59.2 billion | n/a | -2.1% | 0.1% | -1.7% | 0.66 | 3.5% |
| argenx SE ARGX * | $51.1 billion | 42.16 | 17.6% | n/a | 89.9% | 0.00 | n/a |
| Teva Pharmaceutical Industries Ltd. TEVA | $47.9 billion | 68.45 | 9.1% | 9.3% | 4.1% | 2.14 | 0.0% |
| IDEXX Laboratories Inc. IDXX | $40.9 billion | 36.43 | 70.7% | 32.0% | 12.8% | 0.60 | n/a |
| Biogen Inc. BIIB | $33.3 billion | 39.95 | 4.4% | 10.1% | 0.3% | 0.39 | n/a |
| Zoetis Inc. ZTS | $31.0 billion | 12.32 | 83.1% | n/a | 1.5% | 2.87 | 2.7% |
| Roivant Sciences Ltd. ROIV | $25.6 billion | n/a | -6.3% | -7,914.8% | -67.6% | 0.00 | n/a |
| BioNTech SE BNTX * | $24.4 billion | n/a | -5.9% | -49.0% | 4.3% | 0.01 | n/a |
| Genmab A/S GMAB * | $23.8 billion | 24.11 | 16.5% | 28.6% | 19.2% | 0.90 | n/a |
| United Therapeutics Corp. UTHR | $23.5 billion | 19.66 | 20.5% | 44.4% | 2.5% | 0.00 | n/a |
| Viatris Inc. VTRS | $20.3 billion | n/a | -2.9% | -0.6% | 4.4% | 0.81 | 2.7% |
| Exelixis, Inc. EXEL | $14.9 billion | 18.82 | 46.7% | 39.9% | 9.2% | 0.00 | n/a |
| Neurocrine Biosciences Inc. NBIX | $14.5 billion | 20.88 | 19.1% | 23.6% | 34.4% | 0.00 | n/a |
| Jazz Pharmaceuticals plc JAZZ | $14.2 billion | 15.06 | 19.6% | 19.5% | 12.6% | 0.91 | n/a |
| Corcept Therapeutics Inc. CORT | $13.1 billion | 288.38 | 7.8% | 0.8% | 16.0% | 0.00 | n/a |
| Halozyme Therapeutics, Inc. HALO | $12.6 billion | 32.96 | 288.1% | 35.9% | 41.2% | 13.50 | n/a |
| Elanco Animal Health Inc. ELAN | $11.4 billion | n/a | -3.0% | n/a | 12.0% | 0.56 | n/a |
| Bio-Techne Corp. TECH | $11.3 billion | 63.02 | 8.6% | 20.7% | -0.4% | 0.09 | 0.4% |
| Biomarin Pharmaceutical Inc. BMRN | $10.6 billion | 148.11 | 1.2% | 4.4% | 11.2% | 0.66 | n/a |
| Dr. Reddy’s Laboratories Limited RDY * | $10.4 billion | 23.34 | 11.4% | 15.0% | 3.2% | 0.21 | 0.7% |
| Krystal Biotech, Inc. KRYS | $9.8 billion | 41.58 | 17.8% | 44.9% | 22.6% | 0.00 | n/a |
| Repligen Corp. RGEN | $9.8 billion | 238.14 | 2.0% | 8.2% | 16.5% | 0.26 | n/a |
| Protagonist Therapeutics, Inc. PTGX | $9.3 billion | 139.56 | 9.9% | 20.7% | 34.8% | 0.00 | n/a |
| Arrowhead Pharmaceuticals, Inc. ARWR | $8.9 billion | n/a | -68.7% | -33.8% | 16.8% | 1.47 | n/a |
| Cytokinetics Inc. CYTK | $8.7 billion | n/a | n/a | -1,046.1% | -21.1% | n/a | n/a |
| TG Therapeutics, Inc. TGTX | $8.5 billion | 20.21 | 73.1% | 17.1% | 76.1% | 1.23 | n/a |
| Alkermes plc. ALKS | $6.8 billion | 106.92 | 3.7% | 7.0% | 10.8% | 0.84 | n/a |
| Lantheus Holdings, Inc. LNTH | $6.5 billion | 24.19 | 21.0% | 19.4% | 2.3% | 0.43 | n/a |
| Ligand Pharmaceuticals Inc. LGND | $6.0 billion | 32.28 | 20.4% | 32.6% | 54.9% | 1.16 | n/a |
| PTC Therapeutics, Inc. PTCT | $5.4 billion | n/a | n/a | 12.5% | -42.8% | n/a | n/a |
| Indivior Pharmaceuticals, Inc. INDV | $4.2 billion | n/a | n/a | n/a | 13.5% | n/a | n/a |
| Organon & Co. OGN | $3.6 billion | 17.93 | 20.8% | n/a | -2.5% | 8.50 | 2.5% |
| Acadia Pharmaceuticals Inc. ACAD | $3.4 billion | 8.91 | 29.1% | 7.6% | 11.8% | 0.00 | n/a |
| Arcus Biosciences, Inc. RCUS | $3.1 billion | n/a | -99.1% | -415.4% | -55.3% | 0.22 | n/a |
| Neogen Corp. NEOG | $2.6 billion | n/a | -2.7% | -0.8% | -0.3% | 0.37 | n/a |
| Supernus Pharmaceuticals, Inc. SUPN | $2.5 billion | n/a | -10.7% | -15.7% | 24.9% | 0.00 | n/a |
| Liquidia Corp. LQDA | $2.4 billion | 19.99 | 71.0% | 37.4% | 2,233.6% | 0.00 | n/a |
| Harmony Biosciences Holdings, Inc. HRMY | $2.3 billion | 13.09 | 18.1% | 24.0% | 24.3% | 0.15 | n/a |
| Adma Biologics, Inc. ADMA | $2.3 billion | 14.80 | 41.4% | 43.8% | 8.0% | 0.48 | n/a |
| Prestige Consumer Healthcare Inc. PBH | $2.3 billion | 13.52 | 9.0% | 26.3% | -1.4% | 1.05 | n/a |
| Perrigo Co. plc PRGO | $2.1 billion | n/a | -69.0% | -37.7% | -4.2% | 1.31 | 7.7% |
| Vericel Corp. VCEL | $2.1 billion | 85.35 | 6.5% | 6.0% | 23.0% | 0.00 | n/a |
| Vir Biotechnology, Inc. VIR | $2.0 billion | n/a | -25.6% | -92.4% | 1,495.9% | 0.00 | n/a |
| Sarepta Therapeutics, Inc. SRPT | $1.9 billion | n/a | -8.9% | -7.3% | -20.4% | 0.55 | n/a |
| Xencor Inc. XNCR | $1.8 billion | n/a | -32.5% | -205.8% | -28.6% | 0.15 | n/a |
| Schrodinger, Inc. SDGR | $1.7 billion | n/a | -16.5% | -59.2% | 8.9% | 0.00 | n/a |
| ANI Pharmaceuticals Inc. ANIP | $1.7 billion | 15.73 | 18.1% | 15.4% | 30.9% | 1.02 | n/a |
| Phibro Animal Health Corp. PAHC | $1.6 billion | 15.76 | 25.9% | 12.8% | 17.1% | 1.91 | 1.3% |
| Innoviva, Inc. INVA | $1.5 billion | 5.17 | 29.0% | 36.9% | 18.8% | 0.21 | 0.0% |
| Pacira BioSciences, Inc. PCRX | $1.4 billion | 103.76 | 2.2% | 2.7% | 5.7% | 0.54 | n/a |
| Amphastar Pharmaceuticals, Inc. AMPH | $1.1 billion | 15.76 | 10.2% | 15.7% | 1.0% | 0.79 | n/a |
| QuidelOrtho Corp. QDEL | $916 million | n/a | -59.1% | -30.8% | -2.5% | 1.43 | n/a |
| Collegium Pharmaceutical, Inc. COLL | $717 million | 17.79 | 15.4% | 19.5% | 14.3% | 3.50 | n/a |
50 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read more
By market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.Filings
| Filing | Period | Filed | Where |
|---|---|---|---|
| 10-Q | 30 June 2026 | 28 July 2026 | EDGAR |
| 10-Q | 31 March 2026 | 5 May 2026 | EDGAR |
| 10-K | 31 December 2025 | 25 February 2026 | EDGAR |
| 10-Q | 30 September 2025 | 28 October 2025 | EDGAR |
| 10-Q | 30 June 2025 | 29 July 2025 | EDGAR |
| 10-Q | 31 March 2025 | 1 May 2025 | EDGAR |
| 10-K | 31 December 2024 | 12 February 2025 | EDGAR |
| 10-Q | 30 September 2024 | 24 October 2024 | EDGAR |
| 10-Q | 30 June 2024 | 24 July 2024 | EDGAR |
| 10-Q | 31 March 2024 | 1 May 2024 | EDGAR |
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.